A citation-based method for searching scientific literature

A C Antoniou, R Hardy, L Walker, D G Evans, A Shenton, R Eeles, S Shanley, G Pichert, L Izatt, S Rose, F Douglas, D Eccles, P J Morrison, J Scott, R L Zimmern, D F Easton, P D P Pharoah. J Med Genet 2008
Times Cited: 123







List of co-cited articles
778 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
36


A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, F Lalloo. J Med Genet 2004
178
31

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
A C Antoniou, A P Cunningham, J Peto, D G Evans, F Lalloo, S A Narod, H A Risch, J E Eyfjord, J L Hopper, M C Southey,[...]. Br J Cancer 2008
299
31

The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
A C Antoniou, P P D Pharoah, P Smith, D F Easton. Br J Cancer 2004
281
26

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
625
24

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
648
23

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
21

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
A C Antoniou, P D P Pharoah, G McMullan, N E Day, M R Stratton, J Peto, B J Ponder, D F Easton. Br J Cancer 2002
308
20

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
19

Validity of models for predicting BRCA1 and BRCA2 mutations.
Giovanni Parmigiani, Sining Chen, Edwin S Iversen, Tara M Friebel, Dianne M Finkelstein, Hoda Anton-Culver, Argyrios Ziogas, Barbara L Weber, Andrea Eisen, Kathleen E Malone,[...]. Ann Intern Med 2007
74
25

Assessing women at high risk of breast cancer: a review of risk assessment models.
Eitan Amir, Orit C Freedman, Bostjan Seruga, D Gareth Evans. J Natl Cancer Inst 2010
257
19

Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Christine Fischer, Karoline Kuchenb√§cker, Christoph Engel, Silke Zachariae, Kerstin Rhiem, Alfons Meindl, Nils Rahner, Nicola Dikow, Hansj√∂rg Plendl, Irmgard Debatin,[...]. J Med Genet 2013
49
36

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Donald A Berry, Edwin S Iversen, Daniel F Gudbjartsson, Elaine H Hiller, Judy E Garber, Beth N Peshkin, Caryn Lerman, Patrice Watson, Henry T Lynch, Susan G Hilsenbeck,[...]. J Clin Oncol 2002
325
17


Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
J Peto, N Collins, R Barfoot, S Seal, W Warren, N Rahman, D F Easton, C Evans, J Deacon, M R Stratton. J Natl Cancer Inst 1999
629
16

Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Allison W Kurian, Gail D Gong, Esther M John, Alexander Miron, Anna Felberg, Amanda I Phipps, Dee W West, Alice S Whittemore. Cancer Epidemiol Biomarkers Prev 2009
41
36

Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.
B Rockhill, D Spiegelman, C Byrne, D J Hunter, G A Colditz. J Natl Cancer Inst 2001
414
15

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
14

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
Debbie Saslow, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener,[...]. CA Cancer J Clin 2007
14

Assessing BRCA carrier probabilities in extended families.
Carlos H Barcenas, G M Monawar Hosain, Banu Arun, Jihong Zong, Xiaojun Zhou, Jianfang Chen, Jill M Cortada, Gordon B Mills, Gail E Tomlinson, Alexander R Miller,[...]. J Clin Oncol 2006
69
20

Selecting a BRCA risk assessment model for use in a familial cancer clinic.
Seema M Panchal, Marguerite Ennis, Sandra Canon, Louise J Bordeleau. BMC Med Genet 2008
32
43

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
580
13

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
13

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
13

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
824
13

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
A J Lee, A P Cunningham, K B Kuchenbaecker, N Mavaddat, D F Easton, A C Antoniou. Br J Cancer 2014
132
13



Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Nasim Mavaddat, Timothy R Rebbeck, Sunil R Lakhani, Douglas F Easton, Antonis C Antoniou. Breast Cancer Res 2010
44
27

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
319
12

Update on the Manchester Scoring System for BRCA1 and BRCA2 testing.
D G R Evans, F Lalloo, A Wallace, N Rahman. J Med Genet 2005
63
17

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
11

Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
E Thirthagiri, S Y Lee, P Kang, D S Lee, G T Toh, S Selamat, S-Y Yoon, N A Mohd Taib, M K Thong, C H Yip,[...]. Breast Cancer Res 2008
58
18

Performance of BRCA1/2 mutation prediction models in Asian Americans.
Allison W Kurian, Gail D Gong, Nicolette M Chun, Meredith A Mills, Ashley D Staton, Kerry E Kingham, Beth B Crawford, Robin Lee, Salina Chan, Susan S Donlon,[...]. J Clin Oncol 2008
43
23

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
Sheila Seal, Deborah Thompson, Anthony Renwick, Anna Elliott, Patrick Kelly, Rita Barfoot, Tasnim Chagtai, Hiran Jayatilake, Munaza Ahmed, Katarina Spanova,[...]. Nat Genet 2006
487
9

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antonis C Antoniou, Francine Durocher, Paula Smith, Jacques Simard, Douglas F Easton. Breast Cancer Res 2006
59
15

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
S R Young, Robert T Pilarski, Talia Donenberg, Charles Shapiro, Lyn S Hammond, Judith Miller, Karen A Brooks, Stephanie Cohen, Beverly Tenenholz, Damini Desai,[...]. BMC Cancer 2009
167
9

Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
488
9

Limited family structure and BRCA gene mutation status in single cases of breast cancer.
Jeffrey N Weitzel, Veronica I Lagos, Carey A Cullinane, Patricia J Gambol, Julie O Culver, Kathleen R Blazer, Melanie R Palomares, Katrina J Lowstuter, Deborah J MacDonald. JAMA 2007
130
9


Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
488
9


Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
H A Risch, J R McLaughlin, D E Cole, B Rosen, L Bradley, E Kwan, E Jack, D J Vesprini, G Kuperstein, J L Abrahamson,[...]. Am J Hum Genet 2001
712
8

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Hanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, Marijke Wasielewski, Anja de Snoo, Rogier Oldenburg, Antoinette Hollestelle, Mark Houben, Ellen Crepin, Monique van Veghel-Plandsoen,[...]. Nat Genet 2002
767
8


Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
Paul A James, Rebecca Doherty, Marion Harris, Bickol N Mukesh, Alvin Milner, Mary-Anne Young, Clare Scott. J Clin Oncol 2006
88
9

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
F J Couch, M L DeShano, M A Blackwood, K Calzone, J Stopfer, L Campeau, A Ganguly, T Rebbeck, B L Weber. N Engl J Med 1997
520
8

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
8

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
D A Berry, G Parmigiani, J Sanchez, J Schildkraut, E Winer. J Natl Cancer Inst 1997
253
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.